UNLABELLED: Genetic reporters provide a noninvasive method to monitor and evaluate a population of cells. The ideal properties of a gene reporter-probe system include biocompatibility, lack of immunogenicity, low background expression or signal, and high sensitivity of detection. The prostate-specific membrane antigen (PSMA) is an attractive candidate for a genetic reporter as it is a human transmembrane protein with a selective expression pattern, and there are several PSMA imaging agents available for clinical and preclinical applications. We evaluated the use of PSMA as a genetic imaging reporter by comparison to 2 clinically established reporters, the mutant herpes simplex virus type I thymidine kinase and the human sodium-iodide symporter. METHODS: Adenoviruses expressing each reporter were constructed and validated in vitro for expression and function. To compare PSMA with existing imaging reporters, a bilateral Matrigel suspension model was established with nude mice bearing cells equally infected with each reporter or control adenovirus. Dynamic PET was performed, and time-activity curves were generated for each reporter-probe pair. RESULTS: A comparison of peak target-to-background ratios revealed that PSMA offered the highest ratio relative to the control Matrigel suspension as well as muscle. Further, as proof of concept, PSMA was applied as an imaging reporter to monitor adenoviral liver transduction with both nuclear and optical imaging probes. CONCLUSION: These preliminary studies support further development of PSMA as a noninvasive genetic reporter.
UNLABELLED: Genetic reporters provide a noninvasive method to monitor and evaluate a population of cells. The ideal properties of a gene reporter-probe system include biocompatibility, lack of immunogenicity, low background expression or signal, and high sensitivity of detection. The prostate-specific membrane antigen (PSMA) is an attractive candidate for a genetic reporter as it is a human transmembrane protein with a selective expression pattern, and there are several PSMA imaging agents available for clinical and preclinical applications. We evaluated the use of PSMA as a genetic imaging reporter by comparison to 2 clinically established reporters, the mutant herpes simplex virus type I thymidine kinase and the humansodium-iodide symporter. METHODS: Adenoviruses expressing each reporter were constructed and validated in vitro for expression and function. To compare PSMA with existing imaging reporters, a bilateral Matrigel suspension model was established with nude mice bearing cells equally infected with each reporter or control adenovirus. Dynamic PET was performed, and time-activity curves were generated for each reporter-probe pair. RESULTS: A comparison of peak target-to-background ratios revealed that PSMA offered the highest ratio relative to the control Matrigel suspension as well as muscle. Further, as proof of concept, PSMA was applied as an imaging reporter to monitor adenoviral liver transduction with both nuclear and optical imaging probes. CONCLUSION: These preliminary studies support further development of PSMA as a noninvasive genetic reporter.
Authors: Saskia L M A Beeres; Frank M Bengel; Jozef Bartunek; Douwe E Atsma; Jonathan M Hill; Marc Vanderheyden; Martin Penicka; Martin J Schalij; William Wijns; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2007-03-06 Impact factor: 24.094
Authors: Yury Likar; Juan Zurita; Konstantin Dobrenkov; Larissa Shenker; Shangde Cai; Anton Neschadim; Jeffrey A Medin; Michel Sadelain; Hedvig Hricak; Vladimir Ponomarev Journal: J Nucl Med Date: 2010-09 Impact factor: 10.057
Authors: Juri Gelovani Tjuvajev; Mikhail Doubrovin; Timothy Akhurst; Shangde Cai; Julius Balatoni; Mian M Alauddin; Ronald Finn; William Bornmann; Howard Thaler; Peter S Conti; Ronald G Blasberg Journal: J Nucl Med Date: 2002-08 Impact factor: 10.057
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: Sigrid A Rajasekaran; Gopalakrishnapillai Anilkumar; Eri Oshima; James U Bowie; He Liu; Warren Heston; Neil H Bander; Ayyappan K Rajasekaran Journal: Mol Biol Cell Date: 2003-10-03 Impact factor: 4.138
Authors: Akrita Bhatnagar; Yuchuan Wang; Ronnie C Mease; Matthew Gabrielson; Polina Sysa; Il Minn; Gilbert Green; Brian Simmons; Kathleen Gabrielson; Siddik Sarkar; Paul B Fisher; Martin G Pomper Journal: Cancer Res Date: 2014-08-21 Impact factor: 12.701
Authors: Reshani H Perera; Al de Leon; Xinning Wang; Yu Wang; Gopal Ramamurthy; Pubudu Peiris; Eric Abenojar; James P Basilion; Agata A Exner Journal: Nanomedicine Date: 2020-04-26 Impact factor: 5.307
Authors: Yogindra Vedvyas; Enda Shevlin; Marjan Zaman; Irene M Min; Alejandro Amor-Coarasa; Spencer Park; Susan Park; Keon-Woo Kwon; Turner Smith; Yonghua Luo; Dohyun Kim; Young Kim; Benedict Law; Richard Ting; John Babich; Moonsoo M Jin Journal: JCI Insight Date: 2016-11-17
Authors: Il Minn; Mitchell E Menezes; Siddik Sarkar; Keerthi Yarlagadda; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher; Martin G Pomper Journal: Adv Cancer Res Date: 2014 Impact factor: 6.242
Authors: Mark A Sellmyer; Sarah A Richman; Katheryn Lohith; Catherine Hou; Chi-Chang Weng; Robert H Mach; Roddy S O'Connor; Michael C Milone; Michael D Farwell Journal: Mol Ther Date: 2019-10-15 Impact factor: 11.454